Stock listing

Xetra:NVV1 Novavax, Inc. Aktie

German listing (Xetra) of Novavax, Inc. · home listing NASDAQ:NVAX

Follow Novavax, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:NVAX

$7.47 USD -0.49 (-6.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:NVAX

Past year +20.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$7.43 – $7.98 USDNov 20, 2026
Volume
4.73M sharesNov 20, 2026
Market cap
$1.23B USDAt the close on Nov 20, 2026 · price × 165.0M shares outstanding
52-week range
$6.25 – $13.39 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$71.06M USDMedian day 5.89M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Novavax, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NVAX · Home$7.47 USD-0.49 (-6.2%)4,731,111$7.59$7.98$7.43$7.96Close on Nov 20, 2026
Frankfurt:NVV1€6.89 EUR-0.39 (-5.4%)2,620€6.96€7.10€6.89€7.28Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NVAX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.47-0.49-6.2%$7.59$7.98$7.434,731,111
$7.960.000.0%$7.90$8.32$7.854,242,884
$7.96-0.10-1.2%$8.09$8.14$7.883,529,883
$8.06-0.465-5.5%$8.302$8.42$7.984,722,291
$8.525-0.235-2.7%$8.76$8.785$8.354,636,716
$8.76-1.22-12.2%$9.73$9.74$8.756,980,800
$9.98-0.22-2.2%$10.28$10.36$9.8955,892,699
$10.20-0.69-6.3%$10.61$10.71$10.0712,255,121
$10.89+0.11+1.0%$10.83$11.20$10.428,491,763
$10.78+1.00+10.2%$10.06$10.93$9.9956,284,091
$9.78-0.87-8.2%$10.34$10.68$9.4658,199,553
$10.65+0.97+10.0%$10.01$10.67$9.845,958,391
$9.68+0.15+1.6%$9.555$9.95$9.453,461,748
$9.53-0.55-5.5%$10.11$10.38$9.4854,077,126
$10.08-0.39-3.7%$10.29$10.65$9.9154,059,377
$10.47+0.15+1.5%$10.22$10.62$10.192,788,557
$10.32+0.30+3.0%$9.81$10.34$9.744,742,915
$10.02+0.62+6.6%$9.37$10.10$8.956,766,791
$9.40-0.30-3.1%$9.52$9.88$9.264,916,371
$9.70-0.29-2.9%$9.84$9.93$9.624,415,600
$9.99-1.02-9.3%$10.79$10.87$9.5612,251,500
$11.01-0.42-3.7%$11.39$11.46$10.995,440,600
$11.43+0.61+5.6%$10.75$11.57$10.556,526,400
$10.82-0.44-3.9%$11.20$11.99$10.766,206,000
$11.26-1.56-12.2%$12.71$12.84$11.119,891,800
$12.82+0.18+1.4%$12.50$13.25$12.187,366,900
$12.64-0.18-1.4%$12.69$13.34$12.578,545,800
$12.82+0.16+1.3%$12.44$13.13$12.218,395,500
$12.66-0.09-0.7%$12.61$12.96$12.198,501,800
$12.75+1.74+15.8%$11.17$13.04$11.0319,026,400
$11.01-0.21-1.9%$11.01$11.18$10.766,208,300
$11.22-0.10-0.9%$11.01$11.75$10.908,381,200
$11.32-1.24-9.9%$12.35$13.33$10.8819,413,000
$12.56+2.10+20.1%$10.47$13.39$10.2828,701,900
$10.46-0.14-1.3%$10.80$10.86$10.334,023,000
$10.60-0.21-1.9%$10.75$10.98$10.553,147,200
$10.81-0.01-0.1%$10.85$11.10$10.544,564,400
$10.82+0.02+0.2%$10.80$11.11$10.414,069,300
$10.80+0.17+1.6%$10.50$10.98$10.264,455,800
$10.63+0.03+0.3%$10.62$10.79$10.343,909,900
$10.60+0.05+0.5%$10.43$10.85$10.384,353,200
$10.55-0.28-2.6%$10.79$10.95$10.475,767,200
$10.83+0.42+4.0%$10.39$11.09$10.157,578,400
$10.41+0.30+3.0%$10.38$10.70$10.216,131,800
$10.11+0.11+1.1%$9.89$10.15$9.7611,143,300
$10.00+0.65+7.0%$9.62$10.38$9.618,873,000
$9.35+0.12+1.3%$9.35$9.41$9.162,847,700
$9.23-0.36-3.8%$9.50$9.56$9.163,328,500
$9.59+0.17+1.8%$9.38$9.60$9.143,364,900
$9.42+0.12+1.3%$9.29$9.87$9.236,115,700
$9.30-0.55-5.6%$9.64$9.68$9.115,887,700
$9.85-0.34-3.3%$10.02$10.24$9.734,437,500
$10.19-0.03-0.3%$10.10$10.36$9.754,228,900
$10.22-0.12-1.2%$10.50$10.75$10.055,123,200
$10.34+0.02+0.2%$10.42$10.48$9.906,226,600
$10.32+0.20+2.0%$10.28$10.73$9.965,635,800
$10.12+0.75+8.0%$9.20$10.26$9.1910,040,600
$9.37+0.11+1.2%$9.10$9.99$9.097,266,500
$9.26+0.21+2.3%$9.18$9.34$8.894,209,800
$9.05-0.16-1.7%$9.12$9.18$8.923,422,800
$9.21-0.23-2.4%$9.33$9.44$9.133,507,700
$9.44+0.58+6.5%$9.07$9.58$8.937,107,633
$8.86-0.08-0.9%$8.87$8.98$8.265,579,176
$8.94+0.52+6.2%$8.44$9.20$8.4410,441,300
$8.42-0.37-4.2%$8.50$8.66$8.025,976,500

Splits

1 split · NASDAQ:NVAX · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
Xetra:NVV1
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Xetra
Currency
EUR

What changed lately

Latest news

All Novavax, Inc. news

Novavax, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 277 in all · newest Nov 11, 2026 · oldest 2019
Calls
23 calls with a replay · 23 with a transcript · latest Nov 5, 2026
Decks
73 decks · latest Nov 5, 2026

Where Novavax, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NVAX · Home listingNASDAQUnited StatesUSD
gettex:NVV1gettexGermanyEUR
Tradegate:NVV1TradegateGermanyEUR
BOATS:NVAXBOATSUnited StatesUSD
LS Exchange:A2PKMZLS ExchangeGermanyEUR
BMV:NVAXBMVMexicoMXN
Lang & Schwarz:A2PKMZLang & SchwarzGermanyEUR
Frankfurt:NVV1FrankfurtGermanyEUR
LSIN:0A3SLSINUnited KingdomUSD
VIE:NVAXViennaAustriaEUR
Dusseldorf:NVV1DusseldorfGermanyEUR
Stuttgart:NVV1StuttgartGermanyEUR
SIX Swiss:NVAXSIX SwissSwitzerlandCHF
BIVA:NVAXBIVAMexicoMXN
BSESOF:NVV1BSESOFBulgariaEUR
SIX Swiss:NVAX.USDSIX SwissSwitzerlandUSD
BX Swiss:NVV1BX SwissSwitzerlandCHF
Munich:NVV1MunichGermanyEUR
Hamburg:NVV1HamburgGermanyEUR
Hanover:NVV1HanoverGermanyEUR
Xetra:NVV1 · This pageXetraGermanyEUR

Valuation

EV/sales 2.2× against a median of 28.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$902.3M USD
P/E
Loss
EV/sales
2.2×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
77.3%
Operating margin
−21.2%
Net margin
−18.6%
Debt to equity
Negative equity
Beta vs S&P 500
1.98

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Novavax, Inc. · NASDAQ:NVAXUS$1.23BUS$902.3Mn/a2.2×n/an/a−18.6%n/a1.98
Avalyn Pharma Inc. · NASDAQ:AVLNUS$1.26BUS$946.4Mn/an/an/a3.4×n/a0.0×0.12
LB Pharmaceuticals Inc · NASDAQ:LBRXUS$1.26BUS$858.7Mn/an/an/a3.0×n/a0.0×0.81
MannKind Corporation · NASDAQ:MNKDUS$1.24BUS$1.46Bn/a3.5×309×n/a−18.1%n/a1.06
Silence Therapeutics PLC · NASDAQ:SLNUS$1.23BUS$984.6Mn/a2,159×n/a5.7×n/a0.0×1.07
Ocular Therapeutix, Inc. · NASDAQ:OCULUS$1.23BUS$774.9Mn/a15.4×n/a2.8×−648.6%0.2×1.35
Generate Biomedicines, Inc. · NASDAQ:GENBUS$1.22BUS$895.6Mn/a28.1×n/a3.2×−637.0%0.2×1.90
Taysha Gene Therapies, Inc. · NASDAQ:TSHAUS$1.21BUS$837.4Mn/a153×n/a3.4×n/a0.1×1.69
Mineralys Therapeutics, Inc. · NASDAQ:MLYSUS$1.21BUS$585.1Mn/an/an/a2.4×n/a0.0×1.39
GH Research PLC · NASDAQ:GHRSUS$1.20BUS$841.0Mn/an/an/a3.4×n/a0.0×1.28
Vor Biopharma Inc. · NASDAQ:VORUS$1.18BUS$697.4M0.9×n/an/an/an/an/a1.25
Median of the othersUS$1.23BUS$849.9M0.9×28.1×309×3.3×−637.0%0.0×1.27

Forecasts

5 strong buy · 1 hold · 2 sell · 1 strong sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
14.11 USD · Analysts' mean
EPS, year to Dec 2026
-0.051 · 8 analysts
Revenue, year to Dec 2026
473.1M · 8 analysts

Team and board

Officers

OfficerRole
John C. JacobsPresident and Chief Executive Officer
Jim KellyExecutive Vice President, Chief Financial Officer and Treasurer
Mark CaseyExecutive Vice President, Chief Legal Officer
Troy MorganSenior Vice President, Deputy General Counsel & Chief Compliance Officer
Elaine O’HaraExecutive Vice President, Chief Strategy Officer
Ian WatkinsExecutive Vice President, Chief Human Resources Officer
Rick CrowleyExecutive Vice President, Chief Operations Officer
Robert WalkerExecutive Vice President, Head of Research & Development
Silvia TaylorExecutive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden

Board

DirectorRole
Charles NewtonDirector
Gregg AltonDirector
John ShiverDirector
Rachel KingDirector
Richard DouglasDirector
Rick RodgersDirector

Events

Calls

CallWhenStatus
Novavax (NASDAQ:NVAX) Q3 2026 Earnings CallThu, Nov 05, 2026 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q2 2026 Earnings CallThu, Aug 06, 2026 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q1 2026 Earnings CallWed, May 06, 2026 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q4 2025 Earnings CallThu, Feb 26, 2026 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q2 2025 Earnings CallWed, Aug 06, 2025 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q1 2025 Earnings CallThu, May 08, 2025 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q4 2024 Earnings CallThu, Feb 27, 2025 · 8:00 AM ETReplay
Novavax (NASDAQ:NVAX) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q2 2024 Earnings CallThu, Aug 08, 2024 · 11:30 AM ETReplay
All 23 calls
CallWhenStatus
Novavax (NASDAQ:NVAX) Q1 2024 Earnings CallFri, May 10, 2024 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q4 2023 Earnings CallWed, Feb 28, 2024 · 8:00 AM ETReplay
Novavax (NASDAQ:NVAX) Q3 2023 Earnings CallThu, Nov 09, 2023 · 11:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q2 2023 Earnings CallTue, Aug 08, 2023 · 11:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q1 2023 Earnings CallTue, May 09, 2023 · 8:30 AM ETReplay
Novavax (NASDAQ:NVAX) Q4 2022 Earnings CallTue, Feb 28, 2023 · 4:30 PM ETReplay
Novavax (NASDAQ:NVAX) Q3 2022 Earnings CallTue, Nov 08, 2022 · 4:30 PM ETReplay
Novavax (NASDAQ:NVAX) Q2 2022 Earnings CallMon, Aug 08, 2022 · 4:30 PM ETReplay
Novavax (NASDAQ:NVAX) Q1 2022 Earnings CallMon, May 09, 2022 · 4:30 PM ETReplay
Novavax (NASDAQ:NVAX) Q4 2021 Earnings CallMon, Feb 28, 2022 · 4:30 PM ETReplay
Novavax (NASDAQ:NVAX) Q2 2021 Earnings CallThu, Aug 05, 2021 · 4:30 PM ETReplay
Novavax (NASDAQ:NVAX) Q4 2020 Earnings CallMon, Mar 01, 2021 · 7:30 PM ETReplay
Novavax (NASDAQ:NVAX) Q3 2020 Earnings CallMon, Nov 09, 2020 · 7:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−8.2%
Q2 2026Aug 6, 2026 · Before open+0.5%
Q1 2026May 6, 2026 · Before open+15.6%
Q4 2025Feb 26, 2026+6.4%
Q3 2025Nov 6, 2025 · Before open−1.3%
Q2 2025Aug 6, 2025 · Before open+12.6%
Q1 2025May 8, 2025 · Before open+11.9%
Q4 2024Feb 26, 2025 · Before open+2.1%
Q3 2024Nov 12, 2024 · Before open−6.1%
Q2 2024Aug 8, 2024 · Before open+9.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · Before open+98.7%
Q4 2023Feb 28, 2024 · Before open−26.7%
Q3 2023Nov 9, 2023 · Before open−1.3%
Q2 2023Aug 8, 2023 · Before open−3.9%
Q1 2023May 9, 2023 · Before open+27.8%
Q4 2022Feb 28, 2023 · After close−25.9%
Q3 2022Nov 8, 2022 · After close−5.2%
Q2 2022Aug 8, 2022 · After close−29.6%
Q1 2022May 9, 2022 · After close+1.1%
Q4 2021Feb 28, 2022 · After close+0.4%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings30 slidesNov 5, 2026
Q2 2026 Earnings PresentationEarnings29 slidesAug 6, 2026
Q1 2026 Earnings PresentationEarnings34 slidesMay 6, 2026
Q4 2025 Earnings PresentationEarnings35 slidesFeb 26, 2026
J.P. Morgan Healthcare Conference 2026Conference15 slidesJan 12, 2026
Goldman Sachs 46th Annual Global Healthcare Conference (June 2025)Conference24 slidesJun 11, 2025
Q1 2025 Earnings PresentationEarnings18 slidesMay 8, 2025
Investor Presentation (March 2025)Investor deck41 slidesMar 4, 2025
Q4 2024 Earnings PresentationEarnings20 slidesFeb 27, 2025
Investor Presentation (January 2025)Investor deck42 slidesJan 13, 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (November 2024)Investor deck25 slidesNov 20, 2024
Q3 2024 Earnings PresentationEarnings26 slidesNov 12, 2024
Q2 2024 Earnings PresentationEarnings29 slidesAug 8, 2024
Investor Presentation (June 2024)Investor deck22 slidesJun 6, 2024
Q1 2024 Earnings PresentationEarnings33 slidesMay 10, 2024
Q4 2023 Earnings PresentationEarnings24 slidesFeb 28, 2024
J.P. Morgan 42nd Annual Healthcare Conference 2024Conference24 slidesJan 8, 2024
Q3 2023 Earnings PresentationEarnings23 slidesNov 9, 2023
Q2 2023 Earnings PresentationEarnings24 slidesAug 8, 2023
Q1 2023 Earnings PresentationEarnings29 slidesMay 9, 2023
Technical Presentation (April 2022)Technical40 slidesApr 20, 2022
Technical Presentation (February 2022)Technical18 slidesFeb 10, 2022
Investor Presentation (January 2022)Investor deck22 slidesJan 10, 2022
J.P. Morgan 40th Annual Healthcare Conference 2022Conference22 slidesJan 10, 2022
J.P. Morgan 40th Annual Healthcare Conference 2022Conference22 slidesJanuary 2022
Investor Presentation (September 2021)Investor deck71 slidesSeptember 2021
Q2 2021 Earnings PresentationEarnings32 slidesAug 5, 2021
Proxy Contest (May 2021)Proxy contest20 slidesMay 24, 2021
Investor Presentation (May 2021)Investor deck42 slidesMay 2021
Investor Presentation (April 2021)Investor deck33 slidesApril 2021
J.P. Morgan 39th Annual Healthcare Conference - Virtual (January 2021)Conference35 slidesJan 11, 2021
Investor Presentation (December 2020)Investor deck35 slidesDec 1, 2020
Investor Presentation (October 2020)Investor deck30 slidesOct 27, 2020
Investor Presentation (September 2020)Investor deck27 slidesSep 16, 2020
Investor Presentation (September 2020)Investor deck26 slidesSep 10, 2020
Second ISV COVID-19 Vaccines Virtual Congress (July 2020)Conference16 slidesJul 21, 2020
Investor Presentation (June 2020)Investor deck33 slidesJune 2020
World Vaccine Congress Webcast 2020Conference30 slidesMay 18, 2020
Technical Presentation (March 2020)Technical11 slidesMar 24, 2020
Technical Presentation (March 2020)Technical10 slidesMar 24, 2020
J.P. Morgan 38th Annual Healthcare Conference (January 2020)Conference31 slidesJan 16, 2020
Technical Presentation (August 2019)Technical18 slidesAug 8, 2019
37th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 201 (May 2019)Conference17 slidesMay 7, 2019
World Vaccine Congress 2019Conference40 slidesApr 18, 2019
Technical Presentation (February 2019)Technical27 slidesFeb 28, 2019
J.P. Morgan 37th Annual Healthcare Conference (January 2019)Conference31 slidesJanuary 2019
Corporate Update (July 2018)Corporate update39 slidesJuly 2018
J.P. Morgan Healthcare Conference January 2018Conference30 slidesJan 8, 2018
Investor Presentation (November 2017)Investor deck20 slidesNovember 2017
Citi 12th Annual Biotech Conference 2017Conference35 slidesSep 7, 2017

This page holds 50 of 73 decks. Open Decks

Open Decks

Financings

RaiseDate
4.625% Convertible Senior Notes due 2031
Announced: about US$49.7M
Aug 21, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.12B682.2M983.7M1.98B1.15B475.6M18.7M34.3M31.2M15.4M
Cost of revenue73.0M202.7M343.8M902.6M00113.8M173.8M168.4M237.9M
Gross profit1.05B479.4M212.6M696.3M1.15B475.6M-95.2M34.3M31.2M-222.6M
Research and development342.3M391.2M737.5M1.24B2.53B747.0M113.8M173.8M168.4M237.9M
Selling, general and administrative157.5M337.2M468.9M488.7M298.4M145.3M34.4M34.4M34.5M46.5M
Operating income452.8M-248.9M-566.5M-644.7M-1.69B-416.7M-120.6M-173.9M-171.7M-269.1M
Depreciation and amortization28.0M48.0M41.0M29.0M13.0M4.30M5.10M7.40M7.60M7.70M
EBITDA480.8M-200.9M-525.5M-615.7M-1.67B-412.4M-115.5M-166.5M-164.1M-261.4M
Interest expense22.5M20.1M14.4M19.9M21.1M15.1M13.6M13.6M14.1M13.0M
Income before tax442.2M-176.6M-543.0M-653.6M-1.71B-418.3M-132.7M-184.7M-183.8M-280.0M
Income tax1.86M10.9M2.03M4.29M29.2M001.36M2.31M2.32M
Net income440.3M-187.5M-545.1M-657.9M-1.74B-418.3M-132.7M-184.7M-183.8M-280.0M
Earnings per share, basic2.72-1.23-5.41-8.42-23.44-7.27-5.51-9.99-12.56-1.03
Earnings per share, diluted2.58-1.23-5.41-8.42-23.44-7.27-5.51-9.99-12.56-1.03

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents240.6M530.2M568.5M1.34B1.52B553.4M78.8M70.2M106.3M144.4M
Short-term investments494.4M392.9M00157.6M022.0M51.0M91.1M
Receivables106.4M108.3M297.2M82.4M455.0M262.0M7.50M-70.3M37.9M233.0K
Inventory11.5M8.75M41.7M36.7M8.87M-166.7M-83.0M12.0M13.1M15.7M
Current assets978.3M1.13B1.14B1.70B2.16B1.25B97.2M119.3M203.3M287.8M
Property, plant and equipment44.8M138.4M305.8M294.2M225.7M180.0M11.4M28.4M36.0M40.2M
Goodwill113.5M107.5M127.5M126.3M131.5M135.4M51.2M52.0M53.6M51.7M
Total assets1.18B1.56B1.80B2.26B2.58B1.58B173.0M208.0M302.5M394.3M
Accounts payable24.6M41.6M132.6M216.5M127.0M54.3M2.91M9.30M5.61M5.68M
Current liabilities459.9M1.15B1.64B2.46B2.39B579.7M25.8M45.5M73.7M66.4M
Long-term debt244.2M169.7M168.0M166.5M323.5M322.0M320.6M319.2M317.8M316.3M
Total debt244.2M230.4M229.1M549.8M454.0M322.0M321.9M343.8M352.5M345.9M
Total liabilities1.30B2.18B2.51B2.89B2.93B955.3M359.0M375.9M404.2M399.8M
Shareholders' equity-127.8M-623.8M-716.9M-634.1M-351.7M627.2M-186.0M-167.9M-101.7M-5.55M
Shares outstanding162.6M160.4M139.5M86.0M75.8M71.0M32.4M19.2M323.2M271.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-244.6M-87.3M-714.0M-415.9M322.9M-42.5M-136.6M-184.8M-144.5M-258.8M
Capital spending-5.56M-13.1M-58.8M-93.0M-57.5M-54.6M-1.86M-1.37M-4.19M-18.2M
Free cash flow-250.2M-100.3M-772.8M-508.9M265.5M-97.2M-138.5M-186.2M-148.7M-277.0M
Cash from investing-78.3M-204.0M-58.8M-93.0M100.2M-377.8M38.5M28.6M36.0M28.0M
Cash from financing27.7M260.6M4.47M325.0M461.7M984.8M98.4M102.8M64.5M279.8M
Dividends paid-39.1M00
Share buybacks-4.80M589.6M-39.1M98.4M102.8M64.6M3.80M
Change in cash-289.2M-38.5M-765.0M-179.4M879.5M566.6M221.0K-53.5M-43.8M48.8M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
8-K · Current reportOct 29, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 16, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 6, 2026Offer documentSEC
8-K · Current reportAug 6, 2026ResultsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Meeting outcomeSEC
144 · Notice of proposed saleMay 27, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 7, 2026Other filingsSEC
8-K · Current reportMay 6, 2026ResultsSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 27, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 8, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 9, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 9, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 9, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 9, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
8-K · Current reportFeb 26, 2026ResultsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
8-K · Current reportJan 20, 2026Material contractSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
8-K · Current reportNov 6, 2025ResultsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025Current reportSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
8-K · Current reportOct 22, 2025Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 14, 2025Big-stake noticeSEC
8-K · Current reportOct 7, 2025Current reportSEC
8-K · Current reportAug 27, 2025Material contractSEC
8-K · Current reportAug 27, 2025Current reportSEC
8-K · Current reportAug 21, 2025Material contractSEC
8-K · Current reportAug 6, 2025ResultsSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
8-K · Current reportJun 24, 2025Meeting outcomeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Current reportSEC
8-K · Current reportMay 27, 2025Management or board changeSEC
144 · Notice of proposed saleMay 19, 2025Other filingsSEC
8-K · Current reportMay 19, 2025Current reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025Material contractSEC
DEFA14A · Additional proxy materialApr 30, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2025Insider tradeSEC
8-K · Current reportApr 29, 2025Management or board changeSEC
8-K · Current reportApr 23, 2025Current reportSEC
144 · Notice of proposed saleApr 14, 2025Other filingsSEC
8-K · Current reportApr 2, 2025Current reportSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 12, 2025Insider tradeSEC
8-K · Current reportMar 11, 2025Management or board changeSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
8-K · Current reportMar 11, 2025Current reportSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
8-K · Current reportMar 4, 2025Current reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
144/A · Notice of proposed sale, amendedJan 2, 2025Other filingsSEC
8-K · Current reportDec 30, 2024Acquisition or disposalSEC
144 · Notice of proposed saleDec 26, 2024Other filingsSEC
8-K · Current reportDec 18, 2024Material contractSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
144 · Notice of proposed saleDec 13, 2024Other filingsSEC
8-K · Current reportDec 4, 2024Material contractSEC
8-K · Current reportNov 19, 2024Current reportSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 13, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024Current reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportNov 5, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
8-K · Current reportOct 16, 2024Current reportSEC
8-K · Current reportOct 2, 2024Current reportSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
4 · Change in ownershipAug 21, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
S-8 · Registration statement for employee plansAug 8, 2024Offer documentSEC
8-K · Current reportAug 8, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJun 20, 2024Big-stake noticeSEC
144 · Notice of proposed saleJun 18, 2024Other filingsSEC
144 · Notice of proposed saleJun 17, 2024Other filingsSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Management or board changeSEC
8-K · Current reportJun 6, 2024Current reportSEC
DEFA14A · Additional proxy materialJun 4, 2024Meeting noticeSEC
8-K · Current reportMay 23, 2024Management or board changeSEC
DFAN14AMay 20, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedMay 20, 2024Big-stake noticeSEC
4 · Change in ownershipMay 15, 2024Insider tradeSEC
144 · Notice of proposed saleMay 14, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 14, 2024Other filingsSEC
DFAN14AMay 13, 2024Other filingsSEC
8-K · Current reportMay 13, 2024Material contractSEC
8-K · Current reportMay 10, 2024ResultsSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
DFAN14AMay 8, 2024Other filingsSEC
DFAN14AMay 7, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedMay 7, 2024Big-stake noticeSEC
DFAN14AMay 6, 2024Other filingsSEC
PREC14AMay 6, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
8-K · Current reportApr 26, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedApr 15, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeApr 15, 2024Big-stake noticeSEC
4 · Change in ownershipMar 26, 2024Insider tradeSEC
4 · Change in ownershipMar 26, 2024Insider tradeSEC
4 · Change in ownershipMar 26, 2024Insider tradeSEC
4 · Change in ownershipMar 26, 2024Insider tradeSEC
4 · Change in ownershipMar 26, 2024Insider tradeSEC
4 · Change in ownershipMar 26, 2024Insider tradeSEC
8-K · Current reportMar 26, 2024Material contractSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC

This page holds 200 of 1,002 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Novavax, Inc.’s releases · as of Oct 31, 2026

Common shares
165,009,009
Fully diluted
165,009,009

Fully diluted

LineSharesAs of
Common shares165,009,009Oct 31, 2026

Share count over time

CountShares
Oct 31, 2026165,009,009

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard15.8M9.6%US$171MSep 30, 2026
BlackRock15.6M9.5%US$169MSep 30, 2026
Shah Capital Management12.2M7.4%US$132MSep 30, 2026
State Street8.83M5.3%US$95.4MSep 30, 2026
Sanofi6.88M4.2%US$74.4MSep 30, 2026
D. E. Shaw & Co., Inc.5.73M3.5%US$62MSep 30, 2026
Two Sigma5.51M3.3%US$59.6MSep 30, 2026
Geode Capital4.23M2.6%US$45.7MSep 30, 2026
Coatue Management LLC3.84M2.3%US$41.5MSep 30, 2026
Bank of America3.79M2.3%US$41MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Goldman Sachs2.98M1.8%US$32.2MSep 30, 2026
Citadel2.78M1.7%US$30.1MSep 30, 2026
Hrt Financial LP2.58M1.6%US$27.9MSep 30, 2026
Jupiter Asset Management LTD2.47M1.5%US$26.7MSep 30, 2026
UBS1.63M0.99%US$17.6MSep 30, 2026
Invesco1.48M0.90%US$16MSep 30, 2026
Schwab1.44M0.87%US$15.6MSep 30, 2026
TSP Capital Management Group, LLC1.43M0.87%US$15.5MSep 30, 2026
Northern Trust1.43M0.87%US$15.5MSep 30, 2026
Trexquant Investment LP1.33M0.81%US$14.4MSep 30, 2026
Allianz1.18M0.71%US$12.7MSep 30, 2026
Federated Hermes, Inc.1.06M0.64%US$11.5MSep 30, 2026
Millennium1.06M0.64%US$11.5MSep 30, 2026
Jump Financial, LLC906K0.55%US$9.79MSep 30, 2026
Fidelity867K0.53%US$9.38MSep 30, 2026
BNY854K0.52%US$9.24MSep 30, 2026
Barclays772K0.47%US$8.34MSep 30, 2026
Morgan Stanley620K0.38%US$6.7MSep 30, 2026
Franklin Templeton510K0.31%US$5.43MSep 30, 2026
Marshall Wace, LLP462K0.28%US$5MSep 30, 2026
Susquehanna411K0.25%US$4.44MSep 30, 2026
Marshall Financial Group, LLC404K0.24%US$4.37MSep 30, 2026
Nuveen342K0.21%US$3.69MSep 30, 2026
Schonfeld Strategic Advisors LLC341K0.21%US$3.69MSep 30, 2026
Citigroup Inc318K0.19%US$3.44MSep 30, 2026
Voya Investment Management LLC293K0.18%US$3.16MSep 30, 2026
Group One Trading LLC291K0.18%US$3.14MSep 30, 2026
Swiss National Bank283K0.17%US$3.06MSep 30, 2026
Quadrature Capital Ltd243K0.15%US$2.63MSep 30, 2026
T. Rowe Price240K0.15%US$2.6MSep 30, 2026
Weiss Asset Management LP228K0.14%US$2.47MSep 30, 2026
Rhumbline Advisers201K0.12%US$2.17MSep 30, 2026
Rafferty Asset Management, LLC200K0.12%US$2.16MSep 30, 2026
ExodusPoint Capital Management, LP190K0.12%US$2.06MSep 30, 2026
Virtus Investment Advisers, LLC190K0.12%US$2.05MSep 30, 2026
Man Group plc169K0.10%US$1.82MSep 30, 2026
AllianceBernstein161K0.10%US$1.74MSep 30, 2026
AQR Capital Management LLC158K0.10%US$1.7MSep 30, 2026
Sun Life157K0.10%US$1.7MSep 30, 2026
California State Teachers Retirement System157K0.10%US$1.7MSep 30, 2026

This page holds 50 of 253 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF7.53M4.6%US$70.9MJun 30, 2026
Vanguard Total Stock Market Index Fund5.2M3.1%US$49MJun 30, 2026
iShares Russell 2000 ETF3.91M2.4%US$36.9MJun 30, 2026
Vanguard Small-Cap Index Fund3.77M2.3%US$35.5MJun 30, 2026
Vanguard Small-Cap Growth Index Fund2.16M1.3%US$20.4MJun 30, 2026
Vanguard Extended Market Index Fund1.89M1.1%US$17.8MJun 30, 2026
Fidelity Small Cap Index Fund1.67M1.0%US$12.2MJul 31, 2026
iShares Russell 2000 Value ETF1.43M0.87%US$13.5MJun 30, 2026
iShares Biotechnology ETF1.11M0.67%US$10.5MJun 30, 2026
PIMCO RAE US Small Fund1.02M0.62%US$9.57MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund841K0.51%US$9.22MMay 31, 2026
Schwab U.S. Small-Cap ETF786K0.48%US$8.62MMay 31, 2026
Vanguard Russell 2000 Index Fund769K0.47%US$8.44MMay 31, 2026
Federated Hermes MDT Small Cap Core Fund693K0.42%US$5.07MJul 31, 2026
Fidelity Enhanced Small Cap Core ETF533K0.32%US$5.02MJun 30, 2026
Vanguard Health Care Index Fund415K0.25%US$4.55MMay 31, 2026
Schwab Small-Cap Index Fund369K0.22%US$2.7MJul 31, 2026
iShares Genomics Immunology and Healthcare ETF340K0.21%US$2.49MJul 31, 2026
Fidelity Total Market Index Fund307K0.19%US$3.37MMay 31, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF293K0.18%US$2.76MJun 30, 2026
Master Small Cap Index Series272K0.16%US$2.56MJun 30, 2026
WisdomTree U.S. SmallCap Fund264K0.16%US$2.48MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares255K0.15%US$1.87MJul 31, 2026
Fidelity Series Total Market Index Fund247K0.15%US$2.71MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF247K0.15%US$2.33MJun 30, 2026
Fidelity Small Cap Value Index Fund213K0.13%US$2.01MJun 30, 2026
Vanguard Strategic Equity Fund205K0.12%US$1.93MJun 30, 2026
Nuveen Small Cap Blend Index Fund202K0.12%US$1.48MJul 31, 2026
ALPS Medical Breakthroughs ETF168K0.10%US$1.84MMay 31, 2026
EQ/2000 Managed Volatility Portfolio166K0.10%US$1.56MJun 30, 2026
Virtus Biotech Etf153K0.09%US$1.12MJul 31, 2026
Goldman Sachs Small Cap Value Insights Fund152K0.09%US$1.12MJul 31, 2026
Invesco RAFI US 1000 ETF148K0.09%US$1.08MJul 31, 2026
Nuveen Equity Index Fund119K0.07%US$868KJul 31, 2026
Vanguard Russell 2000 Growth Index Fund115K0.07%US$1.26MMay 31, 2026
Goldman Sachs Small Cap Equity Insights Fund112K0.07%US$820KJul 31, 2026
iShares U.S. Small-Cap Equity Factor ETF109K0.07%US$800KJul 31, 2026
LVIP State Street Small-Cap Index Fund108K0.07%US$1.02MJun 30, 2026
MFS Blended Research Small Cap Equity Fund106K0.06%US$1.17MMay 31, 2026
SEI Select Small Cap ETF103K0.06%US$968KJun 30, 2026
Schwab Total Stock Market Index Fund98,3470.06%US$720KJul 31, 2026
Schwab U.S. Broad Market ETF98,2960.06%US$1.08MMay 31, 2026
Fidelity Nasdaq Composite Index Fund97,9440.06%US$1.07MMay 31, 2026
Fidelity ZERO Total Market Index Fund89,9830.05%US$659KJul 31, 2026
Vanguard Balanced Index Fund88,4530.05%US$833KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund79,0780.05%US$745KJun 30, 2026
EQ/Small Company Index Portfolio78,9200.05%US$743KJun 30, 2026
Small Cap Index Fund77,1130.05%US$726KJun 30, 2026
Global X Russell 2000 ETF72,8500.04%US$533KJul 31, 2026
Biotechnology Ultrasector Profund71,5470.04%US$524KJul 31, 2026

This page holds 50 of 160 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.8.40%13.5MDec 31, 2024Schedule 13G
Himanshu H. Shah6.46%10.7MOct 16, 2026Schedule 13D
State Street Corp5.40%8.83MSep 30, 2026Schedule 13G
Vanguard Capital Management LLC5.09%8.31MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Mott
Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Ardelyx, Inc. (Chairman · Since at least Jun 18, 2014); Enliven Therapeutics, Inc. (Director · Mar 11, 2020 – Jun 2, 2022 · Past); Nightstar Therapeutics PLC (Director · Jan 1, 2019 – Jun 7, 2019 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jul 1, 2024 · Past); Epizyme Inc (Director · May 30, 2013 – Aug 12, 2022 · Past); Omthera Pharmaceuticals Inc (Director · Apr 11, 2013 – Jul 18, 2013 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past); Medimmune Inc (Vice Chair. of the Board, CEO, Director · Feb 23, 2006 – Jun 18, 2007 · Past)
Director · Since at least Jun 16, 2020
Gail K. Boudreaux
Other companies: Target Corporation (Director · Since at least Sep 23, 2021); Elevance Health, Inc. (President and CEO · Since at least Nov 20, 2017); Zimmer Biomet Holdings, Inc. (Director · Dec 10, 2012 – Mar 31, 2021 · Past); Xcel Energy Inc. (Director · Mar 1, 2012 – Dec 28, 2017 · Past); UnitedHealth Group Incorporated (EVP & CEO, UnitedHealthcare · May 5, 2008 – Sep 23, 2014 · Past); Genzyme Corp (Director · May 25, 2006 – Apr 4, 2011 · Past)
Director · Jun 17, 2015 – Mar 16, 2017 · Past
Richard Rodgers
Other companies: Opus Genetics, Inc. (Director · Since at least Dec 2, 2014); Ardelyx, Inc. (Director · Since at least Jun 18, 2014); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jul 18, 2023 · Past); Tesaro Inc (Executive VP & CFO · Jun 27, 2012 – Mar 6, 2013 · Past); Abraxis BioScience Inc (Senior Vice President and CFO · Jul 9, 2009 – Jul 13, 2009 · Past); Mgi Pharma Inc (Sr. VP and Controller · Jul 15, 2006 – Jan 28, 2008 · Past)
Director · Since at least Oct 29, 2022
Charles Newton
Other companies: Keros Therapeutics, Inc. (Director · Since at least Feb 26, 2026); Coherus Oncology, Inc. (Director · Since at least May 4, 2022); Lyell Immunopharma, Inc. (Chief Financial Officer · Since at least Jun 16, 2021); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past)
Director · Since at least Apr 25, 2025
Gregory F Covino
Other companies: Tesaro Inc (SVP, CAO, PAO · Aug 13, 2018 – Jan 22, 2019 · Past); Biogen Inc. (VP, Chief Accounting Officer · May 1, 2012 – Mar 1, 2018 · Past); Hubbell Inc (Vice President, Controller · Dec 4, 2006 – Dec 6, 2007 · Past)
EVP, Chief Financial Officer · Nov 16, 2020 – Nov 16, 2020 · Past
Margaret G McGlynn
Other companies: Amicus Therapeutics Inc (Director · Since at least Oct 28, 2009); Vertex Pharmaceuticals Incorporated (Director · May 12, 2011 – May 1, 2023 · Past); Air Products and Chemicals, Inc. (Director · Dec 31, 2005 – Sep 30, 2020 · Past)
Director · Since at least Dec 7, 2020
Mark Casey
Other companies: Mallinckrodt Inc (EVP & Chief Legal Officer · Feb 1, 2018 – Jun 16, 2022 · Past); Aceragen Inc. (Senior VP & General Counsel · Jun 29, 2015 – Jan 3, 2018 · Past); Hologic Inc (SVP, CAO, GC & Secretary · Jan 11, 2008 – Nov 18, 2014 · Past)
Executive Vice President, Chief Legal Officer · Since at least Dec 11, 2023
James Patrick Kelly
Other companies: Supernus Pharmaceuticals, Inc. (Executive Vice-President & CFO · Oct 12, 2020 – Feb 19, 2021 · Past); Vanda Pharmaceuticals Inc. (EVP & Chief Financial Officer · Jan 2, 2020 – Mar 2, 2020 · Past)
EVP, CFO and Treasurer · Since at least Aug 16, 2021
Rachel King
Other companies: Fulcrum Therapeutics, Inc. (Board Member · Since at least Nov 12, 2024); Crescent Biopharma, Inc. (Director · Jan 7, 2016 – May 1, 2024 · Past)
Director · Since at least Oct 31, 2018
Richard H. Douglas
Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Jun 10, 2026); MaxCyte, Inc. (Director · Since at least Dec 22, 2024)
Director · Since at least Jun 20, 2026
All 28 people
PersonSeat
Ian Watkins
Other companies: Mallinckrodt Inc (See Remarks · Nov 11, 2020 – Jun 16, 2022 · Past)
Executive Vice President, Chief Human Resources Officer · Since at least Nov 5, 2026
John C. Jacobs
Other companies: Harmony Biosciences Holdings, Inc. (PRESIDENT, CEO, Director · Aug 18, 2020 – Aug 15, 2022 · Past)
President and Chief Executive Officer · Since at least Jan 23, 2023
John Shiver
Other companies: Icosavax Inc (Director · Jan 3, 2022 – Jun 6, 2023 · Past)
Director · Since at least Mar 10, 2025
Dennis W GengeVP, Treasurer,CFO · Feb 17, 2006 – Feb 17, 2006 · Past
Elaine O’HaraExecutive Vice President, Chief Strategy Officer · Since at least Nov 5, 2026
Gregg AltonDirector · Since at least Jun 20, 2026
Jim KellyExecutive Vice President, Chief Financial Officer and Treasurer · Since at least Jun 1, 2026
Jim RobinsonVP, Technical & Quality Ops. · Aug 2, 2007 – Mar 5, 2009 · Past
John A Herrmann IIIEVP, Chief Legal Officer · Jul 31, 2015 – Dec 14, 2023 · Past
John O Marsh JrDirector · Feb 17, 2006 – Mar 6, 2014 · Past
Rajiv I ModiDirector · Mar 31, 2009 – Jun 16, 2015 · Past
Raymond Joseph HageSr. VP. Commercial Operations · May 4, 2005 – Jul 1, 2009 · Past
Rick CrowleyExecutive Vice President, Chief Operations Officer · Since at least Nov 4, 2026
Rick RodgersDirector · Since at least Jun 23, 2026
Robert WalkerEVP, R&D · Since at least Mar 30, 2026
Silvia TaylorExecutive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden · Since at least Nov 5, 2026
Timothy Jon HahnSVP, Manufacturing · Jun 10, 2013 – Mar 5, 2015 · Past
Troy MorganSenior Vice President, Deputy General Counsel & Chief Compliance Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Novavax, Inc.